INOVIO to Present at Upcoming Scientific Conferences
INOVIO (NASDAQ:INO) announced its participation in two major scientific conferences. At the 36th International Papillomavirus Conference in Edinburgh (Nov 12-15), the company will present research on INO-3107's treatment of recurrent respiratory papillomatosis, including studies on interferon responses and T-cell activity. At the Vaccines Summit in Boston (Nov 13-15), Dr. Dave Liebowitz will deliver a keynote on DNA Medicines Vaccine Platform, focusing on Ebola and respiratory papillomatosis case studies. All conference abstracts will be available on INOVIO's website after presentations.
INOVIO (NASDAQ:INO) ha annunciato la sua partecipazione a due importanti conferenze scientifiche. Alla 36a Conferenza Internazionale sul Papillomavirus a Edimburgo (12-15 novembre), l'azienda presenterà ricerche sul trattamento dell'pecia respiratoria papillomatosa ricorrente con INO-3107, includendo studi sulle risposte all'interferone e sull'attività delle cellule T. Al Vaccines Summit a Boston (13-15 novembre), il Dr. Dave Liebowitz presenterà un discorso principale sulla Piattaforma Vaccinale dei Farmaci DNA, focalizzandosi su studi di caso sull'Ebola e sulla papillomatosi respiratoria. Tutti gli abstract delle conferenze saranno disponibili sul sito web di INOVIO dopo le presentazioni.
INOVIO (NASDAQ:INO) anunció su participación en dos importantes conferencias científicas. En la 36ª Conferencia Internacional sobre el Papilomavirus en Edimburgo (del 12 al 15 de noviembre), la empresa presentará investigaciones sobre el tratamiento de la papillomatosis respiratoria recurrente con INO-3107, incluyendo estudios sobre las respuestas a interferón y la actividad de las células T. En la Cumbre de Vacunas en Boston (del 13 al 15 de noviembre), el Dr. Dave Liebowitz ofrecerá una charla principal sobre la Plataforma de Vacunas de Medicamentos de ADN, centrándose en estudios de caso sobre el Ébola y la papillomatosis respiratoria. Todos los resúmenes de las conferencias estarán disponibles en el sitio web de INOVIO después de las presentaciones.
INOVIO (NASDAQ:INO)는 두 개의 주요 과학 회의에 참가한다고 발표했습니다. 제36회 국제 유두종 바이러스 회의가 에든버러에서 (11월 12-15일) 열리며, 이 회사는 INO-3107을 통한 재발성 호흡기 유두종증 치료에 관한 연구를 발표할 예정이며, 여기에는 인터페론 반응 및 T 세포 활동에 대한 연구가 포함됩니다. 백신 정상 회담는 보스턴에서 (11월 13-15일) 열리며, Dr. Dave Liebowitz는 DNA 의약품 백신 플랫폼에 대한 기조 연설을 할 것이며, 이 연설은 에볼라 및 호흡기 유두종증 사례 연구에 초점을 맞출 것입니다. 모든 회의 초록은 발표 후 INOVIO의 웹사이트에서 확인할 수 있습니다.
INOVIO (NASDAQ:INO) a annoncé sa participation à deux grandes conférences scientifiques. Lors de la 36ème Conférence Internationale sur le Papillomavirus à Édimbourg (du 12 au 15 novembre), l'entreprise présentera des recherches sur le traitement de la papillomatose respiratoire récurrente avec INO-3107, y compris des études sur les réponses à l'interféron et l'activité des cellules T. Lors du Vaccines Summit à Boston (du 13 au 15 novembre), le Dr Dave Liebowitz prononcera un discours principal sur la Plateforme de Vaccins Médicaments ADN, en se concentrant sur des études de cas sur l'Ebola et la papillomatose respiratoire. Tous les résumés des conférences seront disponibles sur le site web d'INOVIO après les présentations.
INOVIO (NASDAQ:INO) hat seine Teilnahme an zwei bedeutenden wissenschaftlichen Konferenzen angekündigt. Auf der 36. Internationalen Papillomavirus-Konferenz in Edinburgh (12.-15. November) wird das Unternehmen Forschung zur Behandlung der wiederkehrenden respiratorischen Papillomatose mit INO-3107 präsentieren, einschließlich Studien zu Interferonreaktionen und T-Zell-Aktivität. Auf dem Vaccines Summit in Boston (13.-15. November) wird Dr. Dave Liebowitz einen Hauptvortrag zur DNA-Medikamente-Impfstoffplattform halten, wobei der Schwerpunkt auf Fallstudien zu Ebola und respiratorischer Papillomatose liegt. Alle Konferenzabstracts werden nach den Präsentationen auf der Website von INOVIO verfügbar sein.
- None.
- None.
36th International Papillomavirus Conference (
Presentation and poster by Dr. Matthew Morrow, VP of Translational Sciences
Abstract Title: Treatment of recurrent respiratory papillomatosis with INO-3107 induces significant enrichment in hallmark interferon alpha, interferon gamma and inflammatory molecular signatures in papilloma tissue of responders
Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development
Abstract Title: Clinical response to INO-3107 treatment for recurrent respiratory papillomatosis is associated with CD4 and CD8 T-Cell activity and cytotoxicity in patient airways
Vaccines Summit (
Keynote presentation by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development
Abstract Title: DNA Medicines Vaccine Platform for both Prophylactic and Therapeutic Applications: Case Studies in Ebola and Recurrent Respiratory Papillomatosis
Abstracts from these conferences will be made available on INOVIO's website following each presentation.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conferences-302297797.html
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
What conferences will INOVIO (INO) present at in November 2024?
What will INOVIO (INO) present about INO-3107 at the Papillomavirus Conference?
What is the topic of INOVIO's (INO) keynote presentation at the 2024 Vaccines Summit?
